bioviva american biotechnology company based bainbridge island washington researching treatments interfere ageing process humans bioviva founded ceo elizabeth parrish appeared wired health london discuss biovivas testing gene therapies targeting hallmarks ageing process stated company built essentially prove therapies work remember bioviva research organisation taking things like gene therapies using like parrishs decision patient zero test companys technology personalized study criticized lauded dr lawrence altman author goes first story selfexperimentation medicine said ns value history youre going license drug based treatment labelled selfexperimentation highly controversial requirements progress human trials started us food drug administration authorize parrishs experiments parrish traveled colombia criticized biovivas release data claiming extension parrishs leukocyte telomeres following therapy stating aforementioned extension within error change telomere measurements dr bradley johnson associate professor pathology lab medicine university pennsylvania said telomere length measurements typically low precision variation measurements around percent range reported telomere lengthening apparently experienced elizabeth altering genetic makeup humans gene therapy lengthening telomeres described dangerous ageing process poorly understood telomeres function maintain chromosomal integrity provide substrate dna replication thereby allowing cellular multiplication however telomere shortening causes shortening cellular lifetime helps avoid cancerous mutations cells duncan baird professor cancer genetics cardiff universitys school medicine states meddling fundamentally important tumorsuppressive mechanism evolved longlived species like doesnt strike particularly good timothy caulfield professor faculty law school public health university alberta characterized biovivas work pseudoscience lacking scientific rigorcitation needed george martin professor pathology university washington agreed adviser company resigned upon hearing parrishs antonio regalado reporter mit technology review states experiment seems likely remembered either new low medical quackery perhaps unlikely start era naive people receive genetic modifications treat disease reverse biovivas research interests based preclinical research enzyme telomerase inhibition telomerase gene therapy utilizing adenoassociated virus spanish national cancer research centre cnio demonstrated several beneficial effects increase median lifespan discussing teams research mar√≠a blasco stated discussion scientist demonstrated gene therapy sufficient delay agerelated pathologies extend median maximum longevity mice many pathologies delayed including cancer translating results human diseases telomere syndromes certain agerelated diseases without effective treatments may interest context clinical trials approved corresponding regulatory however experts draw attention results studies mice always directly transferred httpsenwikipediaorgwikibioviva